Skip to content
TrialScanner

NCT04956224

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

Phase 3CompletedVALNLead

Registry record

Lead sponsor
Valneva Austria GmbH
Conditions
SARS-CoV-2 Virus Infection
Primary completion
Nov 10, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04956224 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04956224: Safety and Immunogenicity of... | TrialScanner